Recent studies have demonstrated that TRPM2 was highly expressed in melanoma, breast cancer, prostate cancer, tongue cancer, neuroblastoma, and kidney cancer (Hopkins et al., 2015; Park et al., 2016). This evidence concerns the gene TRPM2 and kidney cancer.